港股異動丨四環醫藥逆勢飆升超16%,CDK4/6抑制劑“吡洛西利”獲批上市
四環醫藥(0460.HK)盤初逆勢拉昇漲超16%,報0.78港元。消息面上,近日,四環醫藥旗下軒竹生物自主研發的吡洛西利片(商品名:軒悅寧®)獲批乳腺癌單藥及聯合氟維司羣雙適應症,成爲國內唯一擁有單藥適應症的CDK4/6抑制劑。業內人士指出,這不僅直接填補了國產創新藥在這一領域的臨牀空白,更標誌着我國乳腺癌靶向治療進入“中國方案”新階段。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.